Article

OcuSense marks commercial launch of new tear testing system

OcuSense has marked the official commercial launch of its TearLab Osmolarity System, a system that measures and monitors tear osmolarity to diagnose dry eye disease.

OcuSense has marked the official commercial launch of its TearLab Osmolarity System, a system that measures and monitors tear osmolarity to diagnose dry eye disease.

The TearLab system determines osmolarity through the measurement of electrical impedance of tear samples. The System is comprised of three individual components - the TearLab Osmolarity Test Card, the TearLab Reader and the TearLab Pen.

The test requires only 0.05 µL tear film samples, takes about 30 seconds from start to finish, and can be performed by a technician. Once the tears are collected, the pen is docked into the TearLab Reader to provide the osmolarity reading. The "lab-on-a-chip" approach used by the device mitigates the risk of evaporation from altering the osmolarity of the tear sample, an issue that is of particular concern with techniques involving small tear samples.

The TearLab system is now widely available in Europe; it is anticipated to launch in the US sometime during 2009.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.